Spire Healthcare Group (SPI) Price Target Lowered to GBX 290 at Berenberg Bank

Spire Healthcare Group (LON:SPI) had its price objective cut by research analysts at Berenberg Bank from GBX 310 ($4.28) to GBX 290 ($4.01) in a report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 37.05% from the stock’s previous close.

Several other equities research analysts have also weighed in on SPI. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 339 ($4.68) target price on shares of Spire Healthcare Group in a report on Thursday, January 4th. Liberum Capital reaffirmed a “hold” rating and issued a GBX 270 ($3.73) target price on shares of Spire Healthcare Group in a report on Tuesday, January 16th. Numis Securities reissued an “add” rating and set a GBX 296 ($4.09) price objective on shares of Spire Healthcare Group in a report on Tuesday, January 16th. Jefferies Group raised shares of Spire Healthcare Group to a “buy” rating and increased their price objective for the stock from GBX 259 ($3.58) to GBX 290 ($4.01) in a report on Wednesday, January 17th. Finally, Barclays started coverage on shares of Spire Healthcare Group in a report on Friday, February 2nd. They set an “equal weight” rating and a GBX 270 ($3.73) price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of GBX 283.17 ($3.91).

How to Become a New Pot Stock Millionaire

Shares of Spire Healthcare Group stock opened at GBX 211.60 ($2.92) on Thursday. Spire Healthcare Group has a fifty-two week low of GBX 206.40 ($2.85) and a fifty-two week high of GBX 362.10 ($5.00). The firm has a market cap of $874.36 and a PE ratio of 5,290.00.

Spire Healthcare Group (LON:SPI) last posted its earnings results on Friday, March 2nd. The company reported GBX 14.40 ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of GBX 14.60 ($0.20) by GBX (0.20) ($0.00). Spire Healthcare Group had a return on equity of 1.71% and a net margin of 1.85%. The firm had revenue of £931.70 million during the quarter.

In related news, insider Justin Ash acquired 46,500 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were purchased at an average price of GBX 215 ($2.97) per share, with a total value of £99,975 ($138,125.17).

COPYRIGHT VIOLATION WARNING: This news story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3295104/spire-healthcare-group-spi-price-target-lowered-to-gbx-290-at-berenberg-bank.html.

About Spire Healthcare Group

Spire Healthcare Group plc is a United Kingdom-based independent hospital group. The Company provides in-patient, daycase and out-patient care from approximately 40 hospitals, 10 clinics and over two specialist care centers across the United Kingdom. The Company also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform, and a screening service, Lifescan, as well as national pathology services.

Analyst Recommendations for Spire Healthcare Group (LON:SPI)

Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Celanese  Receives New Coverage from Analysts at Barclays
Celanese Receives New Coverage from Analysts at Barclays
Marten Transport  Downgraded to Equal Weight at Stephens
Marten Transport Downgraded to Equal Weight at Stephens
Deutsche Bank Downgrades Church & Dwight  to Hold
Deutsche Bank Downgrades Church & Dwight to Hold
Santander Group  Upgraded by Zacks Investment Research to “Buy”
Santander Group Upgraded by Zacks Investment Research to “Buy”
Macerich  Stock Rating Upgraded by BMO Capital Markets
Macerich Stock Rating Upgraded by BMO Capital Markets
Iberiabank  Downgraded by Zacks Investment Research
Iberiabank Downgraded by Zacks Investment Research


© 2006-2018 Ticker Report. Google+.